People
Cortexyme, Inc. announced changes to its leadership team, including appointing Christopher Lowe as interim chief executive officer.
This week, two biotechnology firms announced new leadership, David Nassif, J.D., and Christophe Bourdon.
One week after Johnna Rossell departed Biogen for Enzyvant, Biogen announced two more members of its board are leaving.
What makes a candidate attractive? For Deschoolmeester, three critical elements stand out: pragmatism, creativity and collaboration.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
After guiding the commercial rollout of embattled Alzheimer’s drug Aduhelm for Biogen, Johanna Rossell has departed the company for a leadership role at Enzyvant.
Galapagos NV has appointed Dr. Paul Stoffelsas as its new chief executive officer, replacing Onno van de Stolpe who is retiring.
The company’s focus is to find somebody with considerable pharmaceutical industry experience to help advance regulatory and commercialization initiatives for leronlimab.
Suliman anticipates filing an Investigational New Drug application with the FDA for the PCD asset this year, and next year filing one for the cystic fibrosis asset.
The data is coming in right away for Alnylam in one of its primary indications, transthyretin-mediated (ATTR) amyloidosis.
PRESS RELEASES